Trial Profile
A Phase 1, Open-Label, Multi-Center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-8M4 Given as Monotherapy in Subjects With Advanced Ovarian Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs AGS 8M4 (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacokinetics
- 08 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jun 2010 Planned end date changed from 1 Sep 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.